Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma. uri icon

authors

  • Plesner, Torben
  • Lisby, Steen
  • Basse, Linda
  • Wang, Jianping
  • Sasser, A Kate
  • Guckert, Mary E
  • de Boer, Carla
  • Khokhar, Nushmia Z
  • Yeh, Howard
  • Clemens, Pamela L
  • Ahmadi, Tahamtan
  • Arkenau, Hendrik-Tobias
  • Lokhorst, Henk M
  • Richardson, Paul G
  • Gimsing, Peter
  • Krejcik, Jakub
  • Lemech, Charlotte
  • Minnema, Monique C
  • Lassen, Ulrik
  • Laubach, Jacob P
  • Palumbo, Antonio

publication date

  • January 1, 2016

published in